{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T03:07:05Z","timestamp":1794452825128,"version":"4.9.1"},"reference-count":45,"publisher":"American Association for Cancer Research (AACR)","issue":"9","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"HHS | NIH | National Cancer Institute","award":["K12 CA088084"],"award-info":[{"award-number":["K12 CA088084"]}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"crossref","award":["RP220416"],"award-info":[{"award-number":["RP220416"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"crossref","award":["RP200356"],"award-info":[{"award-number":["RP200356"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"crossref","award":["RR180035"],"award-info":[{"award-number":["RR180035"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"crossref"}]},{"name":"HHS | NIH | National Cancer Institute","award":["L30 CA171000"],"award-info":[{"award-number":["L30 CA171000"]}]},{"name":"HHS | NIH | National Cancer Institute","award":["K22 CA234406"],"award-info":[{"award-number":["K22 CA234406"]}]},{"name":"HHS | NIH | National Cancer Institute","award":["U24 CA224285"],"award-info":[{"award-number":["U24 CA224285"]}]},{"name":"HHS | NIH | National Cancer Institute","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9,14]]},"abstract":"<jats:p>Identification of circulating tumor DNA (ctDNA) following curative intent therapies is a surrogate for microscopic residual disease for patients with metastatic colorectal cancer (mCRC). Preclinically, in micrometastatic microsatellite stable (MSS) colorectal cancer, increased TGF\u03b2 signaling results in exclusion of antitumor cytotoxic T cells from the tumor microenvironment. Bintrafusp alfa (BA) is a bifunctional fusion protein composed of the extracellular domain of the TGF\u03b2RII receptor (\u201cTGF\u03b2 trap\u201d) and anti-PD-L1 antibody. Patients with liver-limited, MSS mCRC and with detected ctDNA after complete resection of all known tumors and standard-of-care therapy were treated with 1,200 mg of BA intravenously every 14 days for six doses. The primary endpoint was ctDNA clearance. Radiographic characteristics at recurrence were compared using independent t tests to historical data from a similar cohort of patients with liver-limited mCRC who underwent observation. Only 4 of 15 planned patients received BA before the study was stopped early for loss of equipoise. There was no grade \u22653 adverse event. None of the patients cleared ctDNA. All patients developed radiographic recurrence by the first planned restaging. Although not detectable at prior to treatment, TGF\u03b23 was found in circulation in all patients at cycle 2 day 1. Compared with a historical cohort, patients administered BA developed more metastases (15 vs. 2, P = 0.005) and greater tumor volumes (9 cm vs. 2 cm, P = 0.05). Treatment with BA in patients with ctDNA-detected, liver-limited mCRC did not clear ctDNA and was associated with large-volume recurrence, highlighting the potential context-specific complexity of dual TGF\u03b2 and PD-L1 inhibition.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Use of ctDNA to identify patients with micrometastatic disease for therapeutic intervention is feasible. Treatment with BA in patients with liver-limited mCRC and with detectable ctDNA after resection generated rapid progression. Approaches targeting TGF\u03b2 signaling must consider its pathway complexity in future immunotherapy combination strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0194","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T09:19:27Z","timestamp":1660295967000},"page":"979-986","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Bintrafusp Alfa, an Anti-PD-L1:TGF\u03b2 Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer"],"prefix":"10.1158","volume":"2","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4911-2252","authenticated-orcid":true,"given":"Van K.","family":"Morris","sequence":"first","affiliation":[{"name":"1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5377-135X","authenticated-orcid":true,"given":"Michael J.","family":"Overman","sequence":"additional","affiliation":[{"name":"1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lam","sequence":"additional","affiliation":[{"name":"2Department of Medical Oncology and Cancer Services, The University of Melbourne, Melbourne, Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2047-097X","authenticated-orcid":true,"given":"Christine M.","family":"Parseghian","sequence":"additional","affiliation":[{"name":"1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3683-8115","authenticated-orcid":true,"given":"Benny","family":"Johnson","sequence":"additional","affiliation":[{"name":"1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Dasari","sequence":"additional","affiliation":[{"name":"1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanwal","family":"Raghav","sequence":"additional","affiliation":[{"name":"1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan K.","family":"Kee","sequence":"additional","affiliation":[{"name":"1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7887-8484","authenticated-orcid":true,"given":"Ryan","family":"Huey","sequence":"additional","affiliation":[{"name":"1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Wolff","sequence":"additional","affiliation":[{"name":"1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4588-2775","authenticated-orcid":true,"given":"John Paul","family":"Shen","sequence":"additional","affiliation":[{"name":"1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June","family":"Li","sequence":"additional","affiliation":[{"name":"3Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Zorrilla","sequence":"additional","affiliation":[{"name":"1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6035-7288","authenticated-orcid":true,"given":"Ching-Wei D.","family":"Tzeng","sequence":"additional","affiliation":[{"name":"4Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8612-8272","authenticated-orcid":true,"given":"Hop S.","family":"Tran Cao","sequence":"additional","affiliation":[{"name":"4Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Shin","family":"Chun","sequence":"additional","affiliation":[{"name":"4Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy E.","family":"Newhook","sequence":"additional","affiliation":[{"name":"4Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4921-5427","authenticated-orcid":true,"given":"Nicolas","family":"Vauthey","sequence":"additional","affiliation":[{"name":"4Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dzifa","family":"Duose","sequence":"additional","affiliation":[{"name":"5Department of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Luthra","sequence":"additional","affiliation":[{"name":"5Department of Pathology and Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1317-9287","authenticated-orcid":true,"given":"Cara","family":"Haymaker","sequence":"additional","affiliation":[{"name":"3Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9647-3416","authenticated-orcid":true,"given":"Scott","family":"Kopetz","sequence":"additional","affiliation":[{"name":"1Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"2023031315421940700_","first-page":"815","article-title":"[Epidemiology of colorectal cancer liver metastases]","volume":"187","author":"Faivre","year":"2003","journal-title":"Bull Acad Natl Med"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1200\/JCO.2008.20.5278","article-title":"Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy","volume":"27","author":"Kopetz","year":"2009","journal-title":"J Clin Oncol"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF00316981","article-title":"Resection of colorectal liver metastases","volume":"19","author":"Scheele","year":"1995","journal-title":"World J Surg"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00000658-200206000-00002","article-title":"Trends in long-term survival following liver resection for hepatic colorectal metastases","volume":"235","author":"Choti","year":"2002","journal-title":"Ann Surg"},{"key":"2023031315421940700_","first-page":"283","article-title":"Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors","volume":"4","author":"Kanas","year":"2012","journal-title":"Clin Epidemiol"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1097\/SLA.0b013e3181b4539b","article-title":"Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients","volume":"250","author":"de Jong","year":"2009","journal-title":"Ann Surg"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejca.2019.12.023","article-title":"Induction of apoptosis increases sensitivity to detect cancer mutations in plasma","volume":"127","author":"Marques","year":"2020","journal-title":"Eur J Cancer"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"224ra24","DOI":"10.1126\/scitranslmed.3007094","article-title":"Detection of circulating tumor DNA in early- and late-stage human malignancies","volume":"6","author":"Bettegowda","year":"2014","journal-title":"Sci Transl Med"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","article-title":"Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer","volume":"5","author":"Tie","year":"2019","journal-title":"JAMA Oncol"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1001\/jamaoncol.2019.0512","article-title":"Prognostic potential of circulating tumor DNA measurement in postoperative surveillance of nonmetastatic colorectal cancer","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1001\/jamaoncol.2019.0528","article-title":"Analysis of plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer","volume":"5","author":"Reinert","year":"2019","journal-title":"JAMA Oncol"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.12044","article-title":"A priori filtering of post-operative (post-op) circulating tumor DNA (ctDNA) to predict recurrence in post-metastasectomy colorectal cancer patients (CRC pts) without knowledge of tumor genotype","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1093\/annonc\/mdu100","article-title":"Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H)","volume":"25","author":"Goldstein","year":"2014","journal-title":"Ann Oncol"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S1470-2045(19)30027-0","article-title":"Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"20","author":"Eng","year":"2019","journal-title":"Lancet Oncol"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1158\/1078-0432.CCR-14-2339","article-title":"The BRAF and MEK inhibitors dabrafenib and trametinib: effects on immune function and in combination with immunomodulatory antibodies targeting PD-1, PD-L1, and CTLA-4","volume":"21","author":"Liu","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.immuni.2016.01.024","article-title":"MAP kinase inhibition promotes T cell and anti-tumor activity in combination with PD-L1 checkpoint blockade","volume":"44","author":"Ebert","year":"2016","journal-title":"Immunity"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.immuni.2016.02.025","article-title":"Integrative analyses of colorectal cancer show immunoscore is a stronger predictor of patient survival than microsatellite instability","volume":"44","author":"Mlecnik","year":"2016","journal-title":"Immunity"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Science"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/ng.3225","article-title":"Stromal gene expression defines poor-prognosis subtypes in colorectal cancer","volume":"47","author":"Calon","year":"2015","journal-title":"Nat Genet"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature25492","article-title":"TGFbeta drives immune evasion in genetically reconstituted colon cancer metastasis","volume":"554","author":"Tauriello","year":"2018","journal-title":"Nature"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1158\/1078-0432.CCR-17-2653","article-title":"Phase I trial of M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGFbeta, in advanced solid tumors","volume":"24","author":"Strauss","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.8_suppl.TPS127","article-title":"Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC)","author":"Ahn","year":"2019","journal-title":"J Clin Oncol"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"e0140712","DOI":"10.1371\/journal.pone.0140712","article-title":"Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA","volume":"10","author":"Lanman","year":"2015","journal-title":"PLoS One"},{"key":"2023031315421940700_"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"249063","DOI":"10.1155\/2012\/249063","article-title":"The role of TGFbeta signaling in squamous cell cancer: lessons from mouse models","volume":"2012","author":"Glick","year":"2012","journal-title":"J Skin Cancer"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1158\/2159-8290.CD-17-0716","article-title":"Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling","volume":"7","author":"Chaudhuri","year":"2017","journal-title":"Cancer Discov"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s10549-015-3322-6","article-title":"PIK3CA mutations in serum DNA are predictive of recurrence in primary breast cancer patients","volume":"150","author":"Oshiro","year":"2015","journal-title":"Breast Cancer Res Treat"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/cncr.31999","article-title":"Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities","volume":"125","author":"Kanjanapan","year":"2019","journal-title":"Cancer"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.3032","article-title":"Incidence and clinical implications of a new definition of hyperprogression (HPD) with immune checkpoint inhibitors (ICIs) in patients treated in phase 1 (Ph1) trials","author":"Matos","year":"2018","journal-title":"J Clin Oncol"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1158\/1078-0432.CCR-13-2098","article-title":"Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials","volume":"20","author":"Fert\u00e9","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.jmb.2005.10.022","article-title":"Three key residues underlie the differential affinity of the TGFbeta isoforms for the TGFbeta type II receptor","volume":"355","author":"De Crescenzo","year":"2006","journal-title":"J Mol Biol"},{"key":"2023031315421940700_","first-page":"203","article-title":"Crystal structure of the human TbetaR2 ectodomain\u2013TGF-beta3 complex","volume":"9","author":"Hart","year":"2002","journal-title":"Nat Struct Biol"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1158\/1535-7163.MCT-16-0465","article-title":"Biological role and therapeutic targeting of TGF-beta3 in glioblastoma","volume":"16","author":"Seystahl","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1038\/cdd.2017.92","article-title":"TGFbeta pathway limits dedifferentiation following WNT and MAPK pathway activation to suppress intestinal tumourigenesis","volume":"24","author":"Cammareri","year":"2017","journal-title":"Cell Death Differ"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/s41591-020-1131-x","article-title":"Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell elimination","volume":"27","author":"Yu","year":"2021","journal-title":"Nat Med"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/SLA.0000000000002901","article-title":"Circulating free methylated tumor DNA markers for sensitive assessment of tumor burden and early response monitoring in patients receiving systemic chemotherapy for colorectal cancer liver metastasis","volume":"268","author":"Bhangu","year":"2018","journal-title":"Ann Surg"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"67495","DOI":"10.18632\/oncotarget.11317","article-title":"Phase I\/II study of azacitidine and capecitabine\/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin","volume":"7","author":"Overman","year":"2016","journal-title":"Oncotarget"},{"key":"2023031315421940700_","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/cam4.1913","article-title":"Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer","volume":"8","author":"Osumi","year":"2019","journal-title":"Cancer Med"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0194\/3188733\/crc-22-0194.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/9\/979\/3282766\/crc-22-0194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/2\/9\/979\/3282766\/crc-22-0194.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T05:19:52Z","timestamp":1727759992000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/2\/9\/979\/709180\/Bintrafusp-Alfa-an-Anti-PD-L1-TGF-Trap-Fusion"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,14]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9,14]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0194","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.22545018","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545024.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545021.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545027.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550830.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545018.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545030","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6550830","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545024","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545030.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545015","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545027","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545015.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22545021","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,14]]}}}